A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PPG / postprandial plasma glucose

[Related PubMed/MEDLINE]
Total Number of Papers: 188
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PPG  (>> Co-occurring Abbreviation)
Long Form:   postprandial plasma glucose
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Abscisic Acid Treatment in Patients with Prediabetes. ABA, FPG, FPI, HOMA-IR, hs-CRP, IFG, IGT, OGTT
2020 Association between Prediabetes and Renal Dysfunction from a Community-based Prospective Study. eGFR, FPG, HbA1c, IFG, IGT, OR, ROC
2020 Clinical Relevance of Blood Glucose and Gastroesophageal Reflux Symptoms to Depressive Status in Patients with Type 2 Diabetes Mellitus. SDS
2020 Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients. BP, FPG, OHA, T2DM
2020 Effect of Afrezza on Glucose Dynamics During HCL Treatment. DiAs, HCL, s.c
2020 Effect of Atorvastatin on blood ketone levels and glycemic control in patients with type 2 diabetes mellitus: A single arm pilot study. acetyl-CoA, FPG
2020 Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. FPG, HCQ, OD
2020 Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial. AEs, CI, FPG, T2DM, TEAEs
2020 Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. AACE, ADA
10  2020 Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). CSII, CV, FPG, MDI
11  2020 Improvement of germinated brown rice quality with autoclaving treatment. FPG, GABA, GBR, HDL-C, LDL-C, MS, TC, TG
12  2020 Protective effects of rutin on kidney in type 1 diabetic mice. BUN, Col I, CRE, GSH-Px, HE, KWI, MDA, SOD, STZ, TGF-beta1
13  2020 Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2). CI, FPG, T2DM, TREAT-INDIA 2
14  2020 The achievement of comprehensive control targets among type 2 diabetes mellitus patients of different ages. BMI, BP, FPG, HDL-C, LDL-C, OR, T2DM, TC, TG
15  2020 The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. ---
16  2019 A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. DPP-4, FPG, T2DM
17  2019 Adjunctive Effect of Doxycycline with Conventional Periodontal Therapy on Glycemic Level for Chronic Periodontitis with Type 2 Diabetes Mellitus Subjects. CAL, DM, FPG, GI, PI, PPD, SRP
18  2019 Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients. FPG, HOMA, hs-CRP, TNF-alpha
19  2019 Association Between Magnesium Status, Dietary Magnesium Intake, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. FPG, T2DM
20  2019 Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. BMI, FPG, Gla-100, HbA1c, T2DM
21  2019 Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial. iGlarLixi, iGlarLixi, T2DM
22  2019 Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naive type 2 diabetic patients. BMI, FPG, T2D
23  2019 Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. AHI, BMI, ESS, FPG, HbA1c, HDL-C, HOMA-IR, OSAHS, T2DM, TG
24  2019 Effect of Ramadan fasting on glycaemic parameters & body mass index in type II diabetic patients: A meta-analysis. BMI, CIs, FPG, OAD, RF, SMD, T2DM
25  2019 Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. CI, FPG, T2DM, WMD
26  2019 Effects of exercise in combination with autologous bone marrow stem cell transplantation for patients with type 1 diabetes. ABMSCT, FBG, T1D
27  2019 Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study. BI, SMPG, T2D, TEAEs
28  2019 Impaired Glucose-Stimulated Proinsulin Secretion Is an Early Marker of beta-Cell Impairment Before Prediabetes Stage. FPG, GSIS, GSPS, IGT, NGT
29  2019 Influence of Diabetogenic Factors on Fasting and Postprandial Glucose Levels in Patients with Type 2 Diabetes Mellitus. DFs, FPG, FPIS, GE, IR, SPIS, T2D
30  2019 Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes. ---
31  2019 Pharmacy-led interventions to improve medication adherence among adults with diabetes: A systematic review and meta-analysis. FPG, RBG, SMD
32  2019 Polymorphisms in NLRP1 Gene Are Associated with Type 1 Diabetes. FPG, PCR, SNPs, T1D
33  2019 Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study. BMI, FPG, OADs, RCTs, T2DM
34  2019 Risk factors for abnormal postpartum glucose outcome in women with gestational diabetes mellitus diagnosed by modified The International Association of the Diabetes and Pregnancy Study Groups criteria. AGT, CI, GDM, IADPSG, NGT, OGTT, OR
35  2018 A Randomized Controlled Trial to Compare the Effect of Peanuts and Almonds on the Cardio-Metabolic and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus. BMI, FBG, HbA1c, IL-6, LCD, T2DM
36  2018 Association between coronary artery atherosclerosis and plasma glucose levels assessed by dual-source computed tomography. AHA, CAA, CAD, DM, DSCT, FPG, HbA1c, NGR
37  2018 Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. CrI, NMA, SBP, SGLT-2is, T2D
38  2018 Daily Yogurt Consumption Improves Glucose Metabolism and Insulin Sensitivity in Young Nondiabetic Japanese Subjects with Type-2 Diabetes Risk Alleles. GRS, PSI, T2DM
39  2018 Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. CI, IAsp, T1D
40  2018 Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial. BI, BW, SD, SE, SMPG, T2D
41  2018 Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. FPG, T2D
42  2018 Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model. GER, GLP-1, GluRA, IR, QSP
43  2018 Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review. FPG, OCT1, PRISMA, PROSPERO, T2DM
44  2018 Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes. AUCPP, CGM, d-ROMs, FPG, MAGE, MGL, MODD, T2DM
45  2017 A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. CV, GLP-1RAs, T2DM
46  2017 A study evaluating the postprandial plasma glucose control among type 2 diabetes patients attending a teaching hospital in Malaysia. HUSM
47  2017 Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). BB, onset 3, T2D
48  2017 Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering. FBG, GLP, PPS
49  2017 Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. DPP, FPG, GLP-1RAs, RAI, SGLT2
50  2017 Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study. BMI, FPG, T2DM
51  2017 Effect of fibre additions to flatbread flour mixes on glucose kinetics: a randomised controlled trial. CPF, EGP, GG, RaE, RaT, RdT
52  2017 Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). ETD, IAsp
53  2017 Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. ETD, IAsp, RR
54  2017 Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. CGM, CSII, ETD, IAsp, IG
55  2017 Lixisenatide as add-on treatment among patients with different beta-cell function levels as assessed by HOMA-beta index. FPG, HOMA-beta, T2DM
56  2017 Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. ---
57  2017 The association of long-term glycaemic variability versus sustained chronic hyperglycaemia with heart rate-corrected QT interval in patients with type 2 diabetes. FPG
58  2016 Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool. FPG, PPGE
59  2016 Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin. HDL
60  2016 Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. AEs, FPG, T2DM
61  2016 Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. GA, HbA1c
62  2016 Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse beta-cell function in the GetGoal-M and GetGoal-S trials. SUIT, T2D
63  2016 Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes. aPPG, eAG, FPG
64  2016 Extra-Virgin Olive Oil Reduces Glycemic Response to a High-Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial. LGI, low fat, RMA
65  2016 Management of postprandial glucose: Recommended targets and treatment with biphasic insulin. ---
66  2016 Short- and Long-Term Effects of Wholegrain Oat Intake on Weight Management and Glucolipid Metabolism in Overweight Type-2 Diabetics: A Randomized Control Trial. FPG, MD, T2DM, TC
67  2016 Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). FPG, T2DM
68  2016 The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. AE, DPP4-i, FPG, T2D
69  2016 The effect of Astragalus as an adjuvant treatment in type 2 diabetes mellitus: A (preliminary) meta-analysis. AAD, AI, CNKI, FINS, FPG, HbA1c, HOMA-IRI, T2DM
70  2015 Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. FPG
71  2015 Effects of a dietary modification on 2 h postprandial blood glucose in Thai population at risk of type 2 diabetes: An application of the Stages of Change Model. ---
72  2015 Epicardial fat thickness in patients with prediabetes and correlation with other cardiovascular risk markers. BMI, EFT, FPG, HbA1c, HDL, IFG, IGT, LDL, TG, WC
73  2015 Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. DM, FPG, HCB, HCS, SNPs
74  2015 Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option. GLP-1RAs
75  2015 Management of endocrine disease. Effects of telecare intervention on glycemic control in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. CNKI, FPG
76  2015 Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. RTG, SGLT2, UGE
77  2015 Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. T2DM
78  2015 Relationship between a lipoprotein lipase gene polymorphism in placental tissue and insulin resistance in patients with gestational diabetes mellitus. BMI, FINS, FPG, HDL, IR, LDL, LPL, PCR-RFLP, TG
79  2014 A randomised controlled trial of high dose vitamin D in recent-onset type 2 diabetes. DCP, FPG
80  2014 A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus. AUC, HDV-I
81  2014 Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. FPG, gliclazide-MR, MET, OAD, PIO, T2DM
82  2014 Different levels of thyroid hormones between impaired fasting glucose and impaired glucose tolerance: free T3 affects the prevalence of impaired fasting glucose and impaired glucose tolerance in opposite ways. CGI, FT3, FT4, IFG, IGT, NGR
83  2014 Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. FPG, HbA1c, T2DM
84  2014 Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. AEs, FPG, HbA1c, T2DM
85  2014 Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. FPG, HbA1c, MTT, T2DM
86  2014 Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. FPG, OADs, T2DM
87  2014 Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. GLP-1RAs, T2DM
88  2014 Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. 1,5-AG, DPP-4, DPP-4 inhibitor CTG, T2DM
89  2014 Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. AUC, FPG, T2DM
90  2014 Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. ANCOVA, GLP-1, LS, T2DM
91  2014 Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. FPG, FPI, HDL-C, HOMA-IR, LDL-C, TC, TG
92  2014 The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. GLP-1, T2DM
93  2014 The effect of IGF2BP2 gene polymorphisms on pioglitazone response in Chinese type 2 diabetes patients. HDL-C, IGF2BP2, T2DM, TG
94  2014 Trigonella foenum-graecum seeds lowers postprandial blood glucose in overweight and obese individuals. IAUC
95  2013 Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study. FBG, T2DM
96  2013 Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. FDC, FPG, T2D
97  2013 Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study. FPG, IAsp
98  2013 Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. MTT, T2DM
99  2013 Disturbed subjective sleep in Chinese females with type 2 diabetes on insulin therapy. CI, FPG, HbA1c, PSQI
100  2013 Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: a randomized, placebo-controlled trial. HOMA-IR, MetS